Roche Holdings AG's RHHBY Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) met its primary and secondary endpoints. The data showed oral fenebrutinib ...

How can imaging biomarkers enhance our understanding of MS? Dr Anne Cross and Dr Matthew Brier examine MRI advancements that ...

Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of fenebrutinib, and bone marrow transplantation as an effective long-term treatment.

"[These results] show that white matter lesions across all MS patients tend to injure the white matter depression network, which may create a vulnerability for depression in the MS population as a ...

The combination of cortical lesions and central vein sign in MRI increases the specificity and sensitivity for diagnosing multiple sclerosis. This study suggests that CLs and CVS, when used together, ...

Collaborating scientists at the Karolinska Institute and at Stockholm University used a technology called in situ sequencing (ISS) to help reveal at the cellular level how lesions in multiple ...

Between 30 to 50 percent of people living with multiple sclerosis (MS) will experience memory problems but the cause is uncertain. Brain lesions are the hallmark imaging sign used to diagnose MS and ...

–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...

Using advanced methodology, scientists have been able to reveal at the cellular level how lesions in multiple sclerosis develop. Using advanced methodology, scientists in Sweden were able to reveal at ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase II FENopta study evaluating ...